CoChat

Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients

Open access
Marcucci, Katherine T., Jadlowsky, Julie K., Hwang, Wei-Ting, Suhoski-Davis, Megan, Gonzalez, Vanessa E., Kulikovskaya, Irina, Gupta, Minnal, Lacey, Simon F., Plesa, Gabriela, Chew, Anne, Melenhorst, J. Joseph, Levine, Bruce L., June, Carl H. · 2018 · Molecular Therapy
Cited by 136

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Replication-competent retrovirus/lentivirus (RCR/L) and insertional oncogenesis are potential safety risks with integrating viruses in gene-modified cell therapies. As such, the Food and Drug Administration guidances outline RCR/L-monitoring methods throughout the entire gene therapy treatment cycle. We present data for 17 vector lots, 375 manufactured T cell products, and 308 patients post-infusion across both HIV and oncology indications, showing no evidence of RCR/L. Given our data, a Poisson probability model estimates that a single patient, or a group of patients, would need to be followed for at least 52.8 years to observe one positive RCR/L event, highlighting the unlikelihood of RCR/L development. Additionally, we estimate the median time for lentivirus-modified T cell products to fall below the 1% vector sequence threshold in peripheral or whole blood that would trigger vector integration site analysis. These estimated times are 1.4 months in hematologic malignancies, 0.66 month in solid tumors, and 0.92 month in HIV. Based on these considerable safety data in HIV and oncology and recent Biologics License Applications filed for lentiviral-modified T cell products for hematologic malignancies, this may be an opportune time to re-evaluate the current guidelines for T cell gene therapy product testing and long-term patient monitoring.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2017.10.012

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 136

Metadata

Authors
Marcucci, K. T., Jadlowsky, J. K., Hwang, W.-T., Suhoski-Davis, M., Gonzalez, V. E., Kulikovskaya, I., Gupta, M., Lacey, S. F., Plesa, G., Chew, A., Melenhorst, J. J., Levine, B. L., & June, C. H.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2018-01
Volume
26
Issue
1
Pages
269-279
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2766005616
Cited by
136
References
16
FWCI
7.04
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. https://app.cochat.ai/papers/10.1016/j.ymthe.2017.10.012
The paper
Marcucci, K. T., Jadlowsky, J. K., Hwang, W.-T., Suhoski-Davis, M., Gonzalez, V. E., Kulikovskaya, I., Gupta, M., Lacey, S. F., Plesa, G., Chew, A., Melenhorst, J. J., Levine, B. L., & June, C. H. (2018). Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2017.10.012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.